M&A / Deals Halozyme and Vertex sign deal for Hypercon technology Pharmaceutical Business ReviewVertex has licensed the technology for use in up to three drug targets, as part of the agreement.M&A / DealsRead full story pharminent April 8, 2026 (Last updated: April 8, 2026) Pharmaceutical Business Review Vertex has licensed the technology for use in up to three drug targets, as part of the agreement. M&A / DealsRead full story Post navigation Previous: Gilead continues M&A surge with $3.1B deal for ADC specialist TubulisNext: RoosterBio and MineBio team up to expand MSC solutions access in China Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026